A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior

Journal of Clinical Psychopharmacology

Volumn 34, Issue 3, 2014, Pages 355-358

  Chan, Hung Yu ^a,b,c   Ree, Shao Chun ^d,e   Su, Lien Wen ^f   Chen, Jiann Jyh ^a   Chou, Sun Yuan ^a   Chen, Chih Ken ^d,e   Chen, Ying Sheue ^g  

^a Taoyuan Psychiatric Center   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

^f TAIPEI CITY HOSPITAL   (Taiwan)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

agitation; haloperidol; intramuscular; olanzapine; schizophrenia

Indexed keywords

BIPERIDEN; HALOPERIDOL; OLANZAPINE; TRIHEXYPHENIDYL; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ACUTE AGITATED BEHAVIOR; ADULT; AGITATION; ARTICLE; ASIAN; BEHAVIOR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; MALE; MULTICENTER STUDY; PARALLEL DESIGN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME; VOMITING; ACUTE DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR AGITATION; TAIWAN;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; TAIWAN; TREATMENT OUTCOME;

EID: 84900513376     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000120     Document Type: Article

References (11)

1. Foster S, Kessel J, Berman ME, et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol. 1997;12:175-179.
2. Currier GW, Chou JC, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry. 2004;65:386-394.
3. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464-470.
4. Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med. 1997;15:357-365.
5. Mantovani C, Labate CM, Sponholz A Jr, et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? J Clin Psychopharmacol. 2013;33:306-312.
6. Katagiri H, Fujikoshi S, Suzuki T, et al. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. BMC Psychiatry. 2013;13:20.
7. MacDonald K, Wilson M, Minassian A, et al. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. J Clin Psychopharmacol. 2012;32:317-322.
8. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441-448.
9. Hsu WY, Huang SS, Lee BS, et al. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol. 2010;30:230-234.
10. Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003;21:192-198.
11. Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry. 2003;48:716-721.